Bioceramic implant reduces intraocular VEGF levels

Area of Science:

• Ophthalmology
• Biomaterials Science
• Regenerative Medicine

Background:

• Elevated intraocular vascular endothelial growth factor (VEGF) drives diabetic retinopathy.
• Current anti-VEGF injections are effective but burdensome.
• Need for sustained intraocular VEGF suppression exists.

Purpose of the Study:

• To evaluate a novel bioceramic implant for intraocular VEGF absorption.
• To assess the biocompatibility and efficacy of hydroxyapatite for sustained VEGF reduction.

Main Methods:

• Developed a hydroxyapatite bioceramic implant for protein dialysis.
• Conducted in vitro and in vivo studies for VEGF absorption capacity.
• Implanted the device in New Zealand White Cross rabbits for 3 months.

Main Results:

• Preliminary studies confirmed high affinity and capacity for VEGF absorption.
• Implantation showed excellent biocompatibility with no observed inflammation.
• Retinal physiology and histology remained normal post-implantation.

Conclusions:

• Hydroxyapatite bioceramic implants demonstrate potential for sustained intraocular VEGF suppression.
• This approach may offer a less burdensome treatment for diabetic retinopathy.
• Further research is warranted to explore clinical applications.